| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 901.36 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Introdução: A Cardiomiopatia Hipertrófica (CMH) é uma doença congénita
autossómica dominante, caracterizada por uma hipertrofia septal assimétrica onde a
cavidade ventricular esquerda não apresenta dilatação e há desarranjo das fibras
musculares ventriculares, podendo ocorrer arritmias ventriculares malignas, levando a
síncope ou mesmo morte. A Morte Súbita Cardíaca (MSC), por sua vez, é uma cessação
inesperada de atividade cardíaca, associada a um colapso hemodinâmico e morte em
menos de uma hora desde o início dos sintomas numa pessoa sem qualquer condição
potencialmente fatal. Estes dois conceitos estão intrinsecamente relacionados dado que
a CMH é uma das principais causas cardiovasculares de MSC.
Metodologia: Para a realização deste trabalho, efetuou-se a pesquisa na internet de
artigos científicos nos últimos 10 anos, relacionados com o tema utilizando como motor
de busca o PubMed, Elsevier e Scopus. Foram, também, utilizadas as guidelines da
European Society of Cardiology e da American College of Cardiology
Foundation/American Heart Association.
Objetivos: O objetivo principal deste trabalho foi verificar a gestão do doente com CMH
na prevenção da MSC.
Conclusão: Têm-se verificado casos de MSC em pessoas com CMH previamente
classificadas de baixo risco, o que demonstra uma classificação inadequada do risco do
doente. Com isto, conclui-se que é necessária uma modificação das escalas de avaliação
de risco de MSC em doentes com CMH, sendo necessária a valorização de outros fatores
de risco para que esta categorização dos doentes seja apropriada, de modo a prevenir
potenciais complicações.
Introduction: Hypertrophic Cardiomyopathy (CMH) is an autosomal dominant congenital disease, characterized by an asymmetric septal hypertrophy where the left ventricular cavity is not dilated and there is disarray of the ventricular muscle fibers, which can cause malignant ventricular arrhythmias, leading to syncope or even death. Sudden Cardiac Death (MSC), in turn, is an unexpected cessation of cardiac activity, associated with hemodynamic collapse and death within less than an hour of the onset of symptoms in a person without any life-threatening condition. These two concepts are intrinsically related as CMH is one of the main cardiovascular causes of MSC. Methodology: The research approach used on the essay was based on an internet search for scientific article from the last 10 years related to the topic, using PubMed, Elsevier and Scopus as a search engine. The European Society of Cardiology and American College of Cardiology Foundation/American Heart Association guidelines were also used. Objectives: To verify the management of the patient with CMH in the prevention of MSC. Conclusion: There have been cases of MSC in people with CMH previously classified as low risk, which demonstrates an inadequate classification of the patient's risk. With this, it is concluded that a modification of the risk assessment scales of MSC in patients with CMH is important, being necessary to value other risk factors so that this categorization of patients is appropriate, in order to prevent potential complications.
Introduction: Hypertrophic Cardiomyopathy (CMH) is an autosomal dominant congenital disease, characterized by an asymmetric septal hypertrophy where the left ventricular cavity is not dilated and there is disarray of the ventricular muscle fibers, which can cause malignant ventricular arrhythmias, leading to syncope or even death. Sudden Cardiac Death (MSC), in turn, is an unexpected cessation of cardiac activity, associated with hemodynamic collapse and death within less than an hour of the onset of symptoms in a person without any life-threatening condition. These two concepts are intrinsically related as CMH is one of the main cardiovascular causes of MSC. Methodology: The research approach used on the essay was based on an internet search for scientific article from the last 10 years related to the topic, using PubMed, Elsevier and Scopus as a search engine. The European Society of Cardiology and American College of Cardiology Foundation/American Heart Association guidelines were also used. Objectives: To verify the management of the patient with CMH in the prevention of MSC. Conclusion: There have been cases of MSC in people with CMH previously classified as low risk, which demonstrates an inadequate classification of the patient's risk. With this, it is concluded that a modification of the risk assessment scales of MSC in patients with CMH is important, being necessary to value other risk factors so that this categorization of patients is appropriate, in order to prevent potential complications.
Description
Keywords
Cardiomiopatia Hipertrófica Morte Súbita Cardíaca Orientações Clínicas Sinais Sintomas